Source disclosure: February 13, 2026
Nxera Pharma Co.,Ltd. [4565.T]
TOKYO, Feb 13 (Pulse News Wire) – Nxera Pharma CO.,LTD. (4565.T) reported a special loss of ¥24.34 billion related to the impairment of its equity investment in Nxera Pharma UK Limited in its individual consolidated financial statements for the fiscal year ending December 2025.
Under Japanese accounting standards applicable to individual financial statements, the company determined there was a significant decline in the fair value of Nxera Pharma UK Limited's shares, leading to the recognition of the impairment loss. However, this does not affect the consolidated results under IFRS standards used for group financial reporting.
The impairment charge will solely impact the individual financial statements and will be offset in the consolidated financial statements, thus having no effect on the overall performance metrics. Nxera Pharma continues to focus on developing innovative specialty medicines through its proprietary NxWave™ drug discovery platform, addressing unmet medical needs across various therapeutic areas such as obesity, metabolic disorders, neurology, immunology, and inflammation.
AI-translated content. 🟢 Confidence: High See terms • Original filing